Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gabapentin, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; purified talc - gabapentin b&b is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin b&b is indicated for the treatment of neuropathic pain.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide red - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; microcrystalline cellulose; silicon dioxide; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - stribild is indicated as a single tablet regimen for the treatment of hiv infection in treatment-na?ve adults. stribild is also indicated in certain virologically suppressed (hiv1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of stribild (tenofovir df, emtricitabine or elvitegravir). stribild is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - finerenone, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; purified water; purified talc; titanium dioxide; iron oxide yellow - kerendia is indicated to delay progressive decline of kidney function and to reduce the risk of cardiovascular mortality and morbidity in adults with chronic kidney disease (with albuminuria) associated with type 2 diabetes, in addition to standard of care (see section 5.1 pharmacodynamic properties, clinical trials).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - finerenone, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; purified water; purified talc; titanium dioxide; iron oxide red - kerendia is indicated to delay progressive decline of kidney function and to reduce the risk of cardiovascular mortality and morbidity in adults with chronic kidney disease (with albuminuria) associated with type 2 diabetes, in addition to standard of care (see section 5.1 pharmacodynamic properties, clinical trials).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir alafenamide fumarate, quantity: 11.2 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment?na?ve; or virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see 5.1 pharmacodynamic properties, clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of genvoya. genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.